AEM vs ALM

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

ALM's deterministic health scores signal severe financial distress: the Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score raises unquantified bankruptcy risk. Despite strong revenue growth (28% YoY) and a bullish analyst consensus (strong_buy), the company reports a negative profit margin (-216.27%), negative ROE (-57.31%), and negative earnings, rendering valuation metrics like Forward P/E (87.79) and Price/Book (31.95) meaningless. The stock trades at a massive premium to its fundamentals, with no intrinsic value or Graham Number available, suggesting speculative pricing. Insider activity is neutral, and the recent 20.2% one-week decline underscores high volatility and potential overvaluation.